Grifols, S.A. (NASDAQ:GRFS) Short Interest Update

Grifols, S.A. (NASDAQ:GRFS) was the recipient of a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 4,570,000 shares, a decrease of 9.7% from the September 15th total of 5,060,000 shares. Based on an average trading volume of 1,470,000 shares, the days-to-cover ratio is currently 3.1 days. Approximately 1.8% of the company’s stock are sold short.

Hedge Funds Weigh In On Grifols

Several institutional investors and hedge funds have recently modified their holdings of GRFS. GAMMA Investing LLC boosted its holdings in shares of Grifols by 49.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after buying an additional 1,135 shares during the period. Cohen Investment Advisors LLC bought a new stake in shares of Grifols during the first quarter worth approximately $80,000. AQR Capital Management LLC acquired a new position in shares of Grifols in the second quarter valued at approximately $89,000. Cetera Advisors LLC bought a new position in shares of Grifols during the first quarter worth approximately $147,000. Finally, Creative Planning lifted its holdings in Grifols by 26.4% during the 3rd quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 3,614 shares during the last quarter.

Grifols Stock Down 0.2 %

Shares of NASDAQ GRFS traded down $0.02 during midday trading on Wednesday, reaching $8.49. The company’s stock had a trading volume of 456,025 shares, compared to its average volume of 1,988,275. The stock has a 50 day simple moving average of $8.52 and a 200-day simple moving average of $7.65. The company has a current ratio of 1.68, a quick ratio of 0.80 and a debt-to-equity ratio of 1.06. The stock has a market capitalization of $5.84 billion, a price-to-earnings ratio of 8.32 and a beta of 0.50. Grifols has a fifty-two week low of $5.30 and a fifty-two week high of $12.15.

Grifols (NASDAQ:GRFS) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.21). The business had revenue of $1.96 billion for the quarter. Equities research analysts predict that Grifols will post 0.79 earnings per share for the current year.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.